OpenBiome-Finch Collaboration: For Clinical Researchers
What to know about OpenBiome’s collaboration with Finch Therapeutics
OpenBiome has partnered with Finch Therapeutics, a mission-driven microbiome biotechnology company, to help accelerate the development of new microbial therapies. Through our partnership with Finch, we aim to connect academic researchers with the technical and financial resources required to more rapidly identify new patient populations that we can serve with microbial interventions.
Where Finch is not a collaborator, it will not have access to non-public information about OpenBiome research. Because the two organizations share some common resources, we have used several mechanisms to ensure that our research partners have full control over their engagement with Finch.
OpenBiome Scientific Review Board (SRB) includes the following members:
- Robert Rosenbaum, MPA (chair)
- Majdi Osman, MD, MPH
- Shrish Budree, MD
No member of the SRB, nor any other member of the OpenBiome team, will be permitted to share study-specific information – including trial design, clinical outcomes, and any other non-public information – beyond OpenBiome without prior written consent from the collaborator.
Dr. Mark Smith, PhD, OpenBiome’s co-founder, has stepped down from his roles at OpenBiome to serve as the CEO at Finch as of March 1, 2017. He will maintain a seat on the OpenBiome Board of Directors and serve as an advisor to OpenBiome’s Scientific Review Board.
FMT Preparations that is produced after March 1, 2017 will be manufactured by Finch, which will be serving as a contract manufacturer for OpenBiome under an improved quality system and manufacturing environment. As the contract manufacturer, Finch will be involved in the response to any reported adverse events.